Stock Markets March 27, 2026

U.S. Futures Slip as Oil Tops $110; Biotechs and Energy Names See Early Moves

Premarket action shows mixed individual stock performance amid broader market weakness tied to geopolitical risk and higher crude prices

By Leila Farooq CVX
U.S. Futures Slip as Oil Tops $110; Biotechs and Energy Names See Early Moves
CVX

U.S. stock futures opened lower on Friday while crude oil reclaimed levels above $110 a barrel after a presidential extension to a deadline tied to Iranian energy infrastructure failed to calm markets. By mid-morning futures for the Dow, S&P 500 and Nasdaq 100 were all trading down, and a range of individual equities from energy majors to biotech and leisure operators posted notable premarket moves.

Key Points

  • U.S. futures fell Friday as oil climbed above $110 a barrel and a presidential deadline extension tied to Iranian energy infrastructure failed to calm investors - impacts markets broadly, especially energy-related equities.
  • Individual stocks showed sharp premarket moves: Rocket Pharmaceuticals and Lantern Pharma rose following U.S. regulatory actions, while Unity Software advanced after preliminary earnings indicated strength in its AI-driven advertising unit - affects biotech and tech sectors.
  • Two Harbors Investment eased after confirming an acquisition agreement with CrossCountry, and Carnival slipped as investors weigh potential fuel-cost effects from geopolitical tensions - relevant to financials, travel, and leisure sectors.

U.S. stock futures were trading lower on Friday as oil prices rose above $110 a barrel and political developments failed to ease investor concerns. President Donald Trump's extension to a deadline related to possible strikes on Iranian energy infrastructure did not substantially soothe market nerves, and equity futures reflected that unease.

By 07:33 ET (11:33 GMT), futures were down across the major U.S. indexes. The Dow futures contract had fallen by 169 points, or 0.4%, S&P 500 futures were lower by 27 points, or 0.4%, and Nasdaq 100 futures had dropped by 148 points, or 0.6%.


Premarket movers

  • Energy names: Oil majors Chevron and Exxon Mobil were each modestly higher in early trading, as were ConocoPhillips and Occidental Petroleum, reflecting the rebound in crude prices.
  • Carnival Corp.: Shares slipped by more than 1% ahead of the cruise operator's quarterly results, with investors focused on any commentary about how the war involving Iran might affect fuel expenses.
  • Rocket Pharmaceuticals: The stock jumped by roughly 10% after U.S. drug regulators approved the company's therapy for a fatal childhood disorder.
  • Lantern Pharma: Shares rose by over 11% following U.S. regulatory clearance to start a study of a treatment for pediatric brain cancer.
  • Phathom Pharmaceuticals: The gastrointestinal-focused biopharma firm climbed after receiving an upgraded rating from Barclays.
  • Argan: The U.S. power plant builder saw its shares jump after reporting robust fourth-quarter revenue growth.
  • Brown-Forman: The spirits company ticked up after French rival Pernod Ricard confirmed it is in merger talks with the owner of the Jack Daniel's whiskey brand.
  • Unity Software: The stock surged more than 14% after preliminary first-quarter results pointed to strength in its advertising business enhanced by artificial intelligence tools.
  • Two Harbors Investment: Shares dipped following the firm's agreement to be acquired by CrossCountry.

Overall, the early session combined broader macroeconomic and geopolitical pressure with company-specific news, producing a mix of gains and losses across sectors. Energy equities moved higher alongside the uptick in crude prices, while several biotechnology and software names reacted sharply to regulatory and earnings-related developments.

Investors remained attentive to incoming corporate updates as well as unfolding geopolitical headlines that could influence commodity costs and broader market sentiment.

Risks

  • Geopolitical uncertainty tied to Iran and the potential for disruption to energy infrastructure could push oil prices higher, creating cost pressures for fuel-intensive industries such as airlines and cruise operators.
  • Regulatory developments and clinical trial clearances can produce sizable swings in biotech stocks, introducing event-driven volatility to the healthcare sector.
  • Ongoing merger and acquisition negotiations, such as Pernod Ricard's talks involving the owner of the Jack Daniel's brand and CrossCountry's acquisition of Two Harbors, may create short-term share price fluctuations for companies involved.

More from Stock Markets

Plug Power’s CEO Jose Luis Crespo Lays Out Execution Plan to Scale and Reach Profitability Mar 27, 2026 Carnival Lowers Full-Year Profit Guide After Fuel Costs Rise Mar 27, 2026 Mizuho Analyst Sees Market Paralysis as Geopolitical Strains Keep Investors on Sidelines Mar 27, 2026 Widespread Flight Cancellations Persist as Middle East Airspace Disruptions Continue Mar 27, 2026 One and One Green Technologies Shares Jump After Announcing Copper-Gold Tailings Recovery Venture Mar 27, 2026